Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Ganti, A. K., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., Florsheim, C., Gold, K. A., Goldman, J. W., Grecula, J. C., Hann, C., Iams, W., Iyengar, P., Kelly, K., Khalil, M., Koczywas, M., Merritt, R. E., Mohindra, N., Molina, J., Moran, C., Pokharel, S., Puri, S., Qin, A., Rusthoven, C., Sands, J., Santana-Davila, R., Shafique, M., Waqar, S. N., Gregory, K. M., Hughes, M. 1800; 19 (12): 1441-1464

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.

View details for DOI 10.6004/jnccn.2021.0058

View details for PubMedID 34902832